Evogene Reports Second Quarter 2023 Financial Results

About this update from Evogene Ltd.

[{"type":"text","content":"Conference call and webcast: today, August 17, 2023, 9:00 am ET\nREHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.\nOfer Haviv, Evogene's President and Chief Executive Officer, stated: \"The second quarter of 2023 marked a period of remarkable achievements for the Evogene group. It was a pivotal point in the transformation that Evogene has been undergoing since the creation of our three AI tech- engines in 2019. Listing some of the main achievements in this period: announcing the receiving of purchase orders in the aggregate amount of $11.3 million for Casterra's elite castor seeds; execution of a licensing agreement between Lavie Bio and Corteva, which includes an upfront payment of $5 million, in addition to milestone and royalty payments; closing of a financial round for Biomica in the amount of $20 million; significant infrastructure and computational architecture improvements, including new applications, in our tech-engines resulting in new capabilities, and better automation, scalability, and speed; and last but not least, receiving the trust of high quality investors demonstrated by an investment in Evogene's equity in the gross amount of $8.5 million in our recent financing round, all happening in a relatively short timeframe. These are clear signals that the Evogene Group is on the right path to success.\"\nMr. Haviv further stated: \"In parallel, Evogene is increasing its efforts to establish direct collaborations with leading companies in new domains of activity, areas not currently covered by our subsidiaries, for product development leveraging our tech-engines. Although these discussions have only recently begun, the responses we have received to our unique offering have been positive, and we hope that some of these discussions will materialize into collaborative agreements in the near future.\"\nEvogene and Subsidiaries - Highlights\nEvogene Ltd.\nIn July, Evogene successfully concluded a fundraising round, securing total gross proceeds of $8.5 million. The securities issued in this ro...

More updates from Evogene Ltd.